Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population

European Journal of Pharmacology

Volumn 710, Issue 1-3, 2013, Pages 80-84

  Gaikwad, Tejasvita ^a   Ghosh, Kanjaksha ^a   Kulkarni, Bipin ^a   Kulkarni, Vrinda ^b   Ross, Cecil ^c   Shetty, Shrimati ^a  

^a KEM HOSPITAL   (India)

^b BYL NAIR CHARITABLE HOSPITAL   (India)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

CYP2C9; India; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ASIAN; BLEEDING; CONTROLLED STUDY; CYP2C9 GENE; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INDIAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; THROMBOSIS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN; YOUNG ADULT;

EID: 84877668431     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.04.006     Document Type: Article

References (22)

1. Y. Caraco, S. Blotnick, and M. Muszkat CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study Clin. Pharmacol. Ther. 83 2008 460 470
2. M.T. Dang, J. Hambleton, and S.R. Kayser The influence of ethnicity on warfarin dosage requirement Ann. Pharmacother. 39 2005 1008 1012
3. V. Franco, C.A. Polanczyk, N. Clausell, and L.E. Rohde Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols Am. J. Med. 116 2004 651 656
4. C. Geisen, M. Watzka, K. Sittinger, M. Steffens, L. Daugela, E. Seifried, C.R. Müller, T.F. Wienker, and J. Oldenburg VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb. Haemostasis 94 2005 773 779
5. J. Hirsh, J. Dalen, D.R. Anderson, L. Poller, H. Bussey, J. Ansell, and D. Deykin Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range Chest 119 2001 8S 21S
6. C. Kearon, J.S. Ginsberg, M.J. Kovacs, D.R. Anderson, P. Wells, and J.A. Julian Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N. Engl. J. Med. 349 2003 631 639
7. S.C. Lee, S.S. Ng, J. Oldenburg, P.Y. Chong, S. Rost, J.Y. Guo, H.L. Yap, S.C. Rankin, H.B. Khor, T.C. Yeo, K.S. Ng, R. Soong, and B.C. Goh Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population Clin. Pharmacol. Ther. 79 2006 197 205
8. C. Li, U.I. Schwarz, M.D. Ritchie, D.M. Roden, C.M. Stein, and D. Kurnik Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy Blood 113 2009 3925 3930
9. K. Lund, D. Gaffney, R. Spooner, A.M. Etherington, P. Tansey, and R.C. Tait Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates Br. J. Haematol. 158 2012 256 261
10. S. Marsh, C.R. King, R.M. Porche-Sorbet, T.J. Scott-Horton, and C.S. Eby Population variation in VKORC1 haplotype structure J. Thromb. Haemostasis 4 2006 473 474
11. T. Mushiroda, Y. Ohnishi, S. Saito, A. Takahashi, Y. Kikuchi, S. Saito, H. Shimomura, Y. Wanibuchi, T. Suzuki, N. Kamatani, and Y. Nakamura Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients J. Hum. Genet. 51 2006 249 253
12. F. Peyvandi, M. Spreafico, S.M. Siboni, M. Moia, and P.M. Mannucci CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy Clin. Pharmacol. Ther. 75 2004 198 203
13. I.M. Suriapranata, W.Y. Tjong, T. Wang, A. Utama, S.B. Raharjo, Y. Yuniadi, and S.S. Tai Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians BMC Med. Genet. 12 2011 80 88
14. H. Takahashi, G.R. Wilkinson, E.A. Nutescu, T. Morita, M.D. Ritchie, M.G. Scordo, V. Pengo, M. Barban, R. Padrini, I. Ieiri, K. Otsubo, T. Kashima, S. Kimura, S. Kijima, and H. Echizen Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogenet. Genomics 16 2006 101 110
15. V.F. Tapson, T.M. Hyers, A.L. Waldo, D.J. Ballard, R.C. Becker, J.A. Caprini, R. Khetan, A.K. Wittkowsky, K.J. Colgan, and A.C. Shillington Antithrombotic therapy practices in US hospitals in an era of practice guidelines Arch. Intern. Med. 165 2005 1458 1464
16. N.M. Vorob'eva, E.P. Panchenko, E.V. Titaeva, Z.B. Khasanova, N.V. Konovalova, A. Postnov, and A.I. Kirienko Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of haemorrhage Ter. Arkh. 83 2011 59 65
17. D.L. Veenstra, J.H. You, M.J. Rieder, F.M. Farin, H.W. Wilkerson, D.K. Blough, G. Cheng, and A.E. Rettie Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenet. Genomics 15 2005 687 691
18. M. Wadelius, L.Y. Chen, N. Eriksson, S. Bumpstead, J. Ghori, D. Bentley, R. McGinnis, and P. Deloukas Association of warfarin dose with genes involved in its action and metabolism Hum. Genet. 121 2007 23 34
19. P.J. White Patient factors that influence warfarin dose response J. Pharm. Pract. 23 2010 194 204
20. A.K. Wittkowsky Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice Am. J. Manag. Care 10 2004 S297 S306
21. H.Y. Yuan, J.J. Chen, M.T. Lee, J.C. Wung, Y.F. Chen, M.J. Charng, M.J. Lu, C.R. Hung, C.Y. Wei, C.H. Chen, J.Y. Wu, and Y.T. Chen A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum. Mol. Genet. 14 2005 1745 1751
22. S.L. Zhong, X.Y. Yu, Y. Liu, D. Xu, L.P. Mai, H.H. Tan, Q.X. Lin, M. Yang, and S.G. Lin Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients Pharmacogenet. Genomics 22 2012 176 182